- SEK42.40m
- SEK28.72m
- SEK54.22m
Brief: ScandiDos Q1 EBITDA loss widens to SEK 6.5 million
Brief: ScandiDos to start sales of Delta4 Phantom+ in US following FDA approval
Brief: ScandiDos Q4 EBITDA loss widens to SEK 5.1 million
Brief: ScandiDos new share issue oversubscribed
Brief: ScandiDos and ACREO receive SEK 0.5 million grant from Vinnova
Brief: ScandiDos to conduct SEK 24 million rights issue
Brief: Scandidos sells Delta4 Phantom to Accuray